Navigation Links
Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference

ted in fewer COPD exacerbations than was seen with placebo. Taken together, the data from these two presentations demonstrate that Perforomist™ Inhalation Solution will provide a new, safe and effective therapeutic option for long-term maintenance treatment of COPD.

Nicholas J. Gross, MD, PhD, an expert on lung diseases, particularly COPD, was the Principal Investigator for the Phase III pivotal trial. He noted, “The GOLD Guidelines for COPD treatment, issued by the World Health Organization and updated last year, recommend regular treatment with long-acting bronchodilators for patients with moderate to very severe COPD. In my judgment, the results of the rigorous 12-week trial clearly demonstrate that physicians now have a new treatment option that is in accord with these GOLD criteria. Perforomist™ Inhalation Solution gives effective, fast bronchodilation that lasts a full 12 hours, allowing patients to nebulize just twice a day – once in the morning and once in the evening – for convenient, long-term control of their symptoms. And because the product is nebulized, patient quality of life is improved not only through effective disease control, but also through using a type of drug delivery that many patients prefer.”

The new product is the first and only FDA-approved nebulized formoterol fumarate, a well-understood and proven LABA with over 10 million patient-years of exposure. The formoterol fumarate molecule has been used worldwide for more than two decades. Nebulization is a type of drug delivery that converts liquid medication into a mist that patients inhale through a mouthpiece or face mask.

Speaking of the safety findings from the Phase III pivotal trial, Harold S. Nelson, MD, Professor of Medicine, National Jewish Medical and Research Center, said, “One of the challenges of treating patients with moderate to severe COPD is that this population tends to have many serious co-morbidities.
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:4/1/2015)... MELVILLE, N.Y. , April 1, 2015  Henry ... provider of health care products and services to office-based ... completion of its acquisition of scil animal care company ... of animal health laboratory and imaging diagnostic products and ... and Europe.  This transaction was announced on ...
(Date:3/31/2015)... 2015 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... exclusive collaboration and licensing agreement for the development and ... Japan and other select Asian markets with ... to initially develop NBI-98854 in Japan ... tardive dyskinesia. Neurocrine retains full commercial rights to NBI-98854 ...
(Date:3/31/2015)... , March 31, 2015  The increasing ... applications have driven the need for automated ... automated segments are going to replace the ... This study provides the market overview, market ... key trends for the liquid handling market ...
Breaking Medicine Technology:Henry Schein Completes Acquisition of scil animal care 2Henry Schein Completes Acquisition of scil animal care 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4Western European Liquid Handling Market 2
... YORK, July 19, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0574348/European-Medical-Displays-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging This research ... market in terms of the challenges faced ...
... drug companies face a number of obstacles to commercialize ... (FDA) and GMP compliance, to distribution agreements and the ... must be coordinated.  Those issues have just become easier ... VPCI have entered into a joint association.  The collaboration ...
Cached Medicine Technology:European Medical Displays Markets 2European Medical Displays Markets 3European Medical Displays Markets 4Spanish Drug Companies Have New Support Option for the U.S. Market 2
(Date:4/1/2015)... MEETING, PA (PRWEB) April 01, 2015 ... assistance company and a subsidiary of West Corporation, today ... available at http://blog.healthadvocate.com and through the Health ... help healthcare consumers get, and stay, healthy. , “We’re ... contents available to the public,” said Martin Rosen, Executive ...
(Date:4/1/2015)... 2015 Senior Helpers of Central Texas ... Provider of Choice Award by Home Care Pulse. The Best ... given to home care providers who receive the highest satisfaction ... quality in home care. This recognition reassures you that your ... provide you with quality, trustworthy in home care. , In ...
(Date:4/1/2015)... York (PRWEB) April 01, 2015 On May ... will host its annual Educational Institute in Albany, New ... innovations, and initiatives in nursing and feature an address by ... Jean M. Hill Professor, University of Kansas School of Nursing ... The event is being sponsored by the Excelsior College School ...
(Date:4/1/2015)... 2015 Franklin University, one of the ... the establishment of the Greta J. Russell Medical Mutual ... through the generous gift of $100,000 from Medical Mutual ... of Medical Mutual to University representatives, Dr. David ... Advancement & Strategic Relations. , “We are grateful ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 ScooterDirect.com is ... mobility scooters to improve their customers’ lifestyle using electric ... to the special needs of the people, they provide ... people to become independent and enjoy their freedom. Scooterdirect.com ... Scooter at discounted prices. , One of ...
Breaking Medicine News(10 mins):Health News:Health Advocate Launches New Health and Wellness Blog 2Health News:Senior Helpers of Central Texas Awarded Prestigious 2015 Senior Home Care Provider of Choice Award from Home Care Pulse 2Health News:Excelsior College School of Nursing Educational Institute to Influence Nursing Empowerment 2Health News:Excelsior College School of Nursing Educational Institute to Influence Nursing Empowerment 3Health News:Franklin University Receives Gift to Create the Greta J. Russell Medical Mutual of Ohio Scholarship 2Health News:Franklin University Receives Gift to Create the Greta J. Russell Medical Mutual of Ohio Scholarship 3Health News:ScooterDirect.com Offering Pride Go Go Traveller Elite 3 Wheel Scooter 2
... Self-Funding Healthcare Conference and Expo will provide employers and ... options during a June 1-3, 2009 conference in Kansas ... an employer rather than a conference promoter. ... the event to help educate employers and plan sponsors ...
... of imaging techniques, the accuracy of preoperative rectal cancer ... function in rectal cancer patients has become a very ... to be published on March 14, 2009 in the ... factors for 5-year survival after local excision of rectal ...
... typical backgrounds of the patients are diagnosed by radiological ... diagnostic imaging techniques. A typical LCA shows low density ... contrasting effect on arterial phase and does not show ... LCA in magnetic resonance imaging shows almost the same ...
... with atrial fibrillation. In the current edition of ... 164-70), Thomas Bitter and his coauthors from the Ruhr ... in this form of cardiac arrythmia and what the ... polygraphy to investigate whether 150 patients (110 men and ...
... Balance SheetATLANTA, March 20 In a time when ... healthcare centers are finding themselves in the same position ... of available financing is putting a damper on major ... the world,s leading manufacturers of oncology and neurosurgical devices ...
... March 20 Boehringer Ingelheim today announced that ... Phase III Randomized Evaluation of Long term Anticoagulant ... efficacy and safety of the oral direct thrombin ... warfarin (target international normalized ratio, INR, 2-3) for ...
Cached Medicine News:Health News:Deffenbaugh Industries to Host Self-Funding Healthcare Conference in Kansas City 2Health News:Elekta Finds New Interest in Leasing Solutions as Hospitals Debate Capital Purchases 2Health News:Elekta Finds New Interest in Leasing Solutions as Hospitals Debate Capital Purchases 3Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 2Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 3Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 4
The Redi-glaze spectacle magnifier is an aspheric lens, glazed into a standard Keeler LVA frame....
A simple testing set for prescribing aspheric spectacle magnifiers. Redi-glaze lenses are available for instant dispensing which are cut and edged to fit our standard LVA frame....
... Featuring up to ... allows examination in the ... sections plus the option ... for corneal transillumination., ,Filters ...
... on the outstanding optical system of the ... an external fibre optic illumination system with ... a digital camera. The result is an ... ,With the option of capturing stills or ...
Medicine Products: